• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immix Biopharma Inc.

    7/19/24 9:12:46 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMMX alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on July 19, 2024

     

    Registration No. 333-                      

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Immix Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   45-4869378

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    11400 West Olympic Blvd., Suite 200

    Los Angeles, CA

      90064
    (Address of principal executive offices)   (Zip Code)

     

    AMENDED AND RESTATED

    IMMIX BIOPHARMA, INC.

    2021 OMNIBUS EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Ilya Rachman, MD PhD

    Chief Executive Officer

    11400 West Olympic Blvd., Suite 200

    Los Angeles, CA 90064

    (Name and address of agent for service)

     

    (310) 651-8041

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Gabriel Morris

    Chief Financial Officer

    11400 West Olympic Blvd., Suite 200

    Los Angeles, CA 90064

    (310) 651-8041

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, Immix Biopharma, Inc. (“Registrant”) is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 3,000,000 (the “Shares”) additional shares of the Registrant’s common stock, $0.0001 par value per share (the “Common Stock”), for issuance under the Registrant’s Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Plan”), pursuant to an amendment to the Plan increasing the number of shares reserved for issuance thereunder by 3,000,000, effective as of June 11, 2024. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on June 13, 2023 (Registration No. 333-272625) and January 25, 2022 (Registration No. 333-262336). The Shares include (a) 889,000 shares of Common Stock issuable upon the exercise of outstanding options held by officers, directors and employees of the Company; and (b) 2,111,000 shares of Common Stock reserved for future awards under the Plan. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

     

    2

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed with the Commission by the Company are incorporated by reference into this registration statement on Form S-8 (the “Registration Statement”) and are made a part hereof:

     

      (a) The Company’s Annual Report on Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024 (the “Annual Report”);
         
      (b) The Company’s Definitive Proxy Statement on Schedule 14A (to the extent incorporated by reference in to the Annual Report), filed with the SEC on April 29, 2024;
         
      (c) The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 9, 2024;
         
      (d) The Company’s Current Reports on Form 8-K and Form 8-K/A (other than information furnished rather than filed) filed with the SEC on February 5, 2024; February 6, 2024; May 20, 2024; and June 14, 2024;
         
      (e) The description of the Company’s Common Stock included as Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 27, 2023, including any amendment or report filed for the purpose of updating such description; and
         
      (f) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Annual Report referred to in (a) above.

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of filing this Registration Statement and prior to such time as the Company files a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the SEC.

     

    Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for the purpose of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which is also, or is deemed to be, incorporated herein by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 5. Interests of Named Experts and Counsel

     

    None.

     

    Item 8. Exhibits

     

    Reference is made to the attached Exhibit Index, which is incorporated herein by reference.

     

    3

     

     

    Item 9. Undertakings

     

      (a) The Company hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the Form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    However, paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, our company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Los Angeles, State of California on July 19, 2024.

     

      Immix Biopharma, Inc.
       
    Date: July 19, 2024 By: /s/ Ilya Rachman
      Name: Ilya Rachman
      Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the persons whose signature appears below constitute and appoint Ilya Rachman and Gabriel Morris, and each of them, with full power to act without the other, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Ilya Rachman   Chief Executive Officer and Chairman   July 19, 2024
    Ilya Rachman   (Principal Executive Officer)    
             
    /s/ Gabriel Morris   Chief Financial Officer and Director   July 19, 2024
    Gabriel Morris   (Principal Financial and Accounting Officer)    
             
    /s/ Jason Hsu    Director   July 19, 2024
    Jason Hsu        
             
    /s/ Magda Marquet   Director   July 19, 2024
    Magda Marquet        
             
    /s/ Helen C. Adams   Director   July 19, 2024
    Helen C. Adams        
             
    /s/ Carey Ng   Director   July 19, 2024
    Carey Ng        
             
    /s/ Jane Buchan   Director   July 19, 2024
    Jane Buchan        
             
    /s/ Yekaterina Chudnovsky   Director   July 19, 2024
    Yekaterina Chudnovsky        

     

    5

     

     

    EXHIBIT INDEX

     

    Exhibit        Incorporated by Reference   Filed
    No.   Description   Form   File No.   Exhibit   Filing Date   Herewith
    5.1*   Opinion of The Loev Law Firm, PC                    
    23.1*   Consent of KMJ Corbin & Company LLP                   X
    23.2*   Consent of The Loev Law Firm, PC (included in Exhibit 5.1)                   X
    24.1*   Power of Attorney (included on the signature page of this registration statement)                   X
    99.1   Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan***   8-K   001-41159   10.1   06/14/2024    
    99.2   Form of Stock Option Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***                   X
    99.3   Form of Restricted Stock Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***                   X
    99.4   Form of Restricted Stock Unit Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***                   X
    107*   Filing Fee Table                   X

     

    * Filed herewith.
    *** Indicates management contract or compensatory plan or arrangement.

     

    6

     

    Get the next $IMMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMMX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

      Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi

      9/19/24 9:31:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

      LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Sanchorawala is internationally recognized for her pioneering work in development of novel agents to treat AL Amyloidosis, including the establishment of daratumumab as the standard of care. "Therapeutic landscape of AL amyloidosis is evolving. There is a marked progress in survival of patients with AL amyloidosis. However, better and more effective therapies are needed for those relapsing after Daratumumab based treatments. I am

      1/4/24 9:34:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

      Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

      6/10/24 1:09:24 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hsu Jason bought $104,358 worth of shares (47,700 units at $2.19), increasing direct ownership by 6% to 893,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      12/26/24 4:20:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/26/24 4:45:32 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/19/24 8:45:04 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IMMX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMMX
    SEC Filings

    See more
    • SEC Form SC 13G filed by Immix Biopharma Inc.

      SC 13G - Immix Biopharma, Inc. (0001873835) (Subject)

      2/7/24 9:18:36 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Immix Biopharma Inc.

      SC 13D - Immix Biopharma, Inc. (0001873835) (Subject)

      8/30/23 4:15:02 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immix Biopharma Inc. (Amendment)

      SC 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)

      3/2/22 2:57:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

      Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi

      9/19/24 9:31:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

      LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be available for institutional investor meetings during the conference. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company

      6/17/24 9:35:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Immix Biopharma Inc.

      10-Q - Immix Biopharma, Inc. (0001873835) (Filer)

      5/8/25 4:30:31 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Immix Biopharma Inc.

      DEFA14A - Immix Biopharma, Inc. (0001873835) (Filer)

      5/2/25 7:51:44 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immix Biopharma Inc.

      SCHEDULE 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)

      1/29/25 6:17:04 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hsu Jason bought $104,358 worth of shares (47,700 units at $2.19), increasing direct ownership by 6% to 893,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      12/26/24 4:20:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/26/24 4:45:32 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/19/24 8:45:04 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care